

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

RYDEX TECHNOLOGIES LLC,

Plaintiff,

v.

SMITHS MEDICAL, and  
SMITHS MEDICAL ASD, INC.

Defendants.

**Civil Action No.** \_\_\_\_\_

**JURY TRIAL DEMANDED**

**COMPLAINT FOR PATENT INFRINGEMENT**

Plaintiff Rydex Technologies LLC, by way of its Complaint for Patent Infringement (“Complaint”) against Defendant Smiths Medical, and Defendant Smiths Medical ASD, Inc., collectively referred to as (“Defendants”), alleges the following:

**NATURE OF THE ACTION**

1. This is an action for patent infringement arising under the patent laws of the United States, 35 U.S.C. § 1 *et seq.*

**THE PARTIES**

2. Plaintiff Rydex Technologies LLC (“Rydex”) is a limited liability company organized under the laws of the State of Delaware with a place of business at 113 Barksdale Professional Center, Newark, Delaware 19711.

3. Upon information and belief, Defendant Smiths Medical is a corporation organized under the laws of Minnesota, with its principal place of business at 1265 Grey Fox Road, St. Paul, Minnesota 55112. Upon information and belief, Defendant Smiths Medical sells and offers to sell products and services throughout the United States, including in this judicial

district, and introduces products and services that perform infringing processes into the stream of commerce knowing that they would be sold in this judicial district and elsewhere in the United States.

4. Upon information and belief, Defendant Smiths Medical ASD, Inc. is a corporation organized under the laws of Delaware, with its principal place of business at 9 Riverside Road, Weston, Massachusetts 02493. Upon information and belief, Defendant Smiths Medical ASD, Inc. sells and offers to sell products and services throughout the United States, including in this judicial district, and introduces products and services that perform infringing processes into the stream of commerce knowing that they would be sold in this judicial district and elsewhere in the United States.

#### **JURISDICTION AND VENUE**

5. This is an action for patent infringement arising under the Patent Laws of the United States, Title 35 of the United States Code.

6. This Court has subject matter jurisdiction under 28 U.S.C. §§ 1331 and 1338(a).

7. Venue is proper in this judicial district under 28 U.S.C. §§ 1391(c) and 1400(b).

8. Upon information and belief, Defendants conduct substantial business in this forum, directly or through intermediaries, including: (i) at least a portion of the infringements alleged herein; and (ii) regularly doing or soliciting business, engaging in other persistent courses of conduct and/or deriving substantial revenue from goods and services provided to individuals in Delaware. Further, this Court has personal jurisdiction over Defendant Smiths Medical ASD, Inc. because it is incorporated in Delaware and has purposely availed itself of the privileges and benefits of the laws of the State of Delaware.

**COUNT I – INFRINGEMENT OF U.S. PATENT NO. 5,913,180 C1**

9. The allegations set forth in the foregoing paragraphs 1 through 8 are hereby realleged and incorporated herein by reference.

10. On June 15, 1999, U.S. Patent No. 5,913,180, entitled “Fluid Delivery Control Nozzle,” was duly and legally issued by the United States Patent and Trademark Office. A true and correct copy of such patent is attached as Exhibit A to this Complaint. On April 26, 2011, re-examination certificate 5,913,180 C1 was duly and legally issued by the United States Patent and Trademark Office (the original patent along with re-exam certificate are collectively referred to herein as the “’180 Patent”). A true and correct copy of the reexamination certificate is attached as Exhibit B to this Complaint.

11. Rydex is the assignee and owner of the right, title and interest in and to the ’180 Patent, including the right to assert all causes of action arising under said patent and the right to any remedies for infringement of it.

12. Upon information and belief, Defendants have and continue to directly infringe one or more claims of the ’180 Patent by making, using, selling, importing, and/or providing and causing to be used products that have the capability to wirelessly transmit information regarding a fluid delivery to a remote device, which by way of example include the Medfusion 3500 Syringe Pump and Medfusion 4000 Wireless Syringe Pump (the “Accused Instrumentalities”).

13. Defendant Smiths Medical was made aware of the ’180 Patent and Defendants’ infringement thereof at least as early as its receipt of correspondence from Rydex providing notice of the ’180 patent and Defendants’ infringement thereof, sent to Defendant Smiths Medical on April 5, 2013. This letter was sent by FedEx 2-day Mail with a tracking number. Rydex has since confirmation of delivery of the letter on April 9, 2013, indicating that Defendants, as related companies, each have notice of the ’180 Patent and their infringement.

14. Upon information and belief, since at least the time they received notice, Defendants have induced and continues to induce others to infringe at least one claim of the '180 Patent under 35 U.S.C. § 271(b) by, among other things, and with specific intent or willful blindness, actively aiding and abetting others to infringe, including but not limited to Defendants' partners and customers, whose use of the Accused Instrumentalities constitutes direct infringement of at least one claim of the '180 Patent.

15. In particular, Defendants' actions that aid and abet others such as its partners and customers to infringe include advertising and distributing the Accused Instrumentalities and providing instruction materials, training, and services regarding the Accused Instrumentalities. On information and belief, Defendants have engaged in such actions with specific intent to cause infringement or with willful blindness to the resulting infringement because Defendants have had actual knowledge of the '180 Patent and that their acts were inducing their customers to infringe the '180 Patent since at least the date Defendants received notice from Rydex notifying Defendants that such activities infringed the '180 Patent.

16. Despite Rydex's notice regarding the '180 Patent, Defendants have continued to infringe the '180 Patent. On information and belief, Defendants' infringement has been and continues to be willful.

17. Rydex has been harmed by Defendants' infringing activities.

#### **JURY DEMAND**

Pursuant to Rule 38 of the Federal Rules of Civil Procedure, Rydex demands a trial by jury on all issues triable as such.

#### **PRAYER FOR RELIEF**

WHEREFORE, Plaintiff Rydex demands judgment for itself and against Defendants as

follows:

- A. An adjudication that Defendants have infringed the '180 Patent;
- B. An award of damages to be paid by Defendants adequate to compensate Rydex for their past infringement of the '180 Patent, and any continuing or future infringement through the date such judgment is entered, including interest, costs, expenses and an accounting of all infringing acts including, but not limited to, those acts not presented at trial;
- C. A declaration that this case is exceptional under 35 U.S.C. § 285, and an award of Plaintiff's reasonable attorneys' fees; and
- D. An award to Rydex of such further relief at law or in equity as the Court deems just and proper.

Dated: April 16, 2013

STAMOULIS & WEINBLATT LLC

/s/ Stamatios Stamoulis

Stamatios Stamoulis #4606

stamoulis@swdelaw.com

Richard C. Weinblatt #5080

weinblatt@swdelaw.com

Two Fox Point Centre

6 Denny Road, Suite 307

Wilmington, DE 19809

Telephone: (302) 999-1540

*Attorneys for Plaintiff*

*Rydex Technologies LLC*